Acorda Therapeutics's revenue for the
three
months ended in Dec. 2023 was $38.0 Mil.
Its revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $117.6 Mil.
Acorda Therapeutics's Revenue per Share for the
three
months ended in Dec. 2023 was $30.58.
Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $95.08.
Warning Sign:
Acorda Therapeutics Inc revenue per share has been in decline for the last 5 years.
During the past 12 months, the average Revenue per Share Growth Rate of Acorda Therapeutics was -19.20% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -37.00% per year.
During the past 5 years, the average Revenue per Share Growth Rate was -39.10% per year.
During the past 10 years, the average Revenue per Share Growth Rate was -23.60% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.
During the past 13 years, Acorda Therapeutics's highest 3-Year average Revenue per Share Growth Rate was 73.50% per year. The lowest was -59.70% per year. And the median was -2.50% per year.
Acorda Therapeutics Revenue Historical Data
The historical data trend for Acorda Therapeutics's Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Acorda Therapeutics's Revenue
For the Drug Manufacturers - Specialty & Generic subindustry, Acorda Therapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Acorda Therapeutics's Revenue Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Acorda Therapeutics's Revenue distribution charts can be found below:
* The bar in red indicates where Acorda Therapeutics's Revenue falls into.
Acorda Therapeutics Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $117.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Acorda Therapeutics Revenue Related Terms
Thank you for viewing the detailed overview of Acorda Therapeutics's Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Acorda Therapeutics (Acorda Therapeutics) Business Description
Acorda Therapeutics Inc is a biopharmaceutical company engaged in developing therapies that restore function and improve the lives of people with neurological disorders. The company market Inbrija (levodopa inhalation powder), which is approved in the U.S. for intermittent treatment of OFF episodes, also known as OFF periods, in people with Parkinson's disease treated with carbidopa/levodopa. Inbrija is for as-needed use and utilizes the ARCUS pulmonary delivery system, a technology platform designed to deliver medication through inhalation. The company also markets branded Ampyra (dalfampridine) Extended-Release Tablets, 10 mg to improve walking in adults with multiple sclerosis.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ACORQ has been successfully added to your 